Mosaic Neurofibromatosis Type 1 in Children: A Single-Institution Experience

被引:4
|
作者
Lara-Corrales, Irene [1 ]
Moazzami, Mitra [1 ]
Garcia-Romero, Maria Teresa [1 ]
Pope, Elena [1 ]
Parkin, Patricia [2 ]
Shugar, Andrea [3 ]
Kannu, Peter [3 ]
机构
[1] Univ Toronto, Hosp Sick Children, Dermatol Sect, Dept Pediat Med, Toronto, ON, Canada
[2] Univ Toronto, Hosp Sick Children, Dept Paediat Med, Toronto, ON, Canada
[3] Univ Toronto, Hosp Sick Children, Div Clin & Metab Genet, Dept Mol Genet, Toronto, ON, Canada
关键词
genodermatosis; neurofibromatosis type 1; segmental neurofibromatosis type 1; mosaic neurofibromatosis type 1; NF1;
D O I
10.1177/1203475417708163
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Neurofibromatosis type 1 (NF1) is a neurocutaneous disorder caused by loss-of-function mutation in the NF1 gene. Segmental or mosaic NF1 (MNF) is an uncommon presentation of the NF1 result of postzygotic mutations that present with subtle localised clinical findings. Objectives: Our study's objectives were to describe the clinical characteristics of children with MNF. Methods: We conducted a cross-sectional study of children diagnosed with MNF at the Hospital for Sick Children in Toronto, Canada, from January 1992 to September 2012. Data were abstracted from health records and analysed using a standardised data collection form approved by our hospital Research Ethics Board. Results: We identified 60 patients with MNF; 32 of 60 (53.3%) were female. Mean SD age at first assessment was 10.6 +/- 4.6 years. The most common initial physical manifestation in 39 of 60 (65.0%) patients was localised pigmentary changes only, followed by plexiform neurofibromas only in 10 of 60 (16.7%) and neurofibromas only in 9 of 60 (15.0%). Unilateral findings were seen in 46 of 60 (76.7%) patients. Most common associations identified included learning disabilities (7/60; 12%) and bony abnormalities (6/60; 10.0%). Conclusions: MNF is an underrecognised condition with potential implications for patients. Children mostly present with pigmentary anomalies only. Most patients do not develop associated findings or complications before adulthood, but long-term follow-up will help determine outcomes and possible associations. Recognition and confirmation of the diagnosis is important to provide follow-up and genetic counselling to patients.
引用
收藏
页码:379 / 382
页数:4
相关论文
共 50 条
  • [1] Lipomas in neurofibromatosis type 1: a single-institution experience
    Miraglia, Emanuele
    Calvieri, Stefano
    Giustini, Sandra
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2020, 155 (03): : 375 - 376
  • [2] Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience
    Espirito Santo, Vera
    Passos, Joao
    Nzwalo, Hipolito
    Carvalho, Ines
    Santos, Filipa
    Martins, Carmo
    Salgado, Lucilia
    Silva, Conceicao e
    Vinhais, Sofia
    Vilares, Miguel
    Salgado, Duarte
    Nunes, Sofia
    JOURNAL OF NEURO-ONCOLOGY, 2020, 147 (02) : 459 - 463
  • [3] Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience
    Vera Espírito Santo
    João Passos
    Hipólito Nzwalo
    Inês Carvalho
    Filipa Santos
    Carmo Martins
    Lucília Salgado
    Conceição e Silva
    Sofia Vinhais
    Miguel Vilares
    Duarte Salgado
    Sofia Nunes
    Journal of Neuro-Oncology, 2020, 147 : 459 - 463
  • [4] SELUMETINIB FOR SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS IN NEUROFIBROMATOSIS TYPE 1: A SINGLE-INSTITUTION EXPERIENCE
    Vazquez-Gomez, Felisa
    Perez-Somarriba, Marta
    Castellano, Serafin
    Moreno, Jose Luis
    Cartas, Susana
    Cantarin, Veronica
    Duat, Anna
    Borrego, Pedro
    Solis, Ines
    Valls, Isabel
    Hernandez, Angela
    Torrelo, Antonio
    Esteso, Borja
    Tamariz-Martel, Amalia
    Egea, Rosa Maria
    Blasco, Luis
    Colmenero, Isabel
    Arce, Begona
    Rivero, Belen
    Madero, Luis
    Lassaletta, Alvaro
    NEURO-ONCOLOGY, 2024, 26
  • [5] Pediatric low-grade glioma and neurofibromatosis type 1: A single-institution experience
    Ruggiero, Antonio
    Attina, Giorgio
    Campanelli, Anastasia
    Maurizi, Palma
    Triarico, Silvia
    Romano, Alberto
    Massimi, Luca
    Tamburrini, Gianpiero
    Verdolotti, Tommaso
    Mastrangelo, Stefano
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (02) : 228 - 234
  • [6] GLIOBLASTOMA IN CHILDREN: A SINGLE-INSTITUTION EXPERIENCE
    Perkins, Stephanie M.
    Rubin, Joshua B.
    Leonard, Jeffrey R.
    Smyth, Matthew D.
    El Naqa, Issam
    Michalski, Jeff M.
    Simpson, Joseph R.
    Limbrick, David L.
    Park, Tae S.
    Mansur, David B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (04): : 1117 - 1121
  • [7] Brain metastases in children with neuroblastoma - A single-institution experience
    Jaing, TH
    Yang, CP
    Hung, IJ
    Wang, HS
    Tseng, CK
    Hsueh, C
    MEDICAL AND PEDIATRIC ONCOLOGY, 2003, 41 (06): : 570 - 571
  • [8] Neurofibromatosis Type 1 in Children: A Single-Center Experience
    Kacar, Ayse Gonca
    Oktay, Burcu Kilinc
    Ozel, Simge Cinar
    Ocak, Suheyla
    Gunes, Nilay
    Alkaya, Dilek Uludag
    Tuysuz, Beyhan
    Apak, Hilmi
    Celkan, Tulin Tiraje
    TURKISH ARCHIVES OF PEDIATRICS, 2021, 56 (04): : 339 - 343
  • [9] SINGLE-INSTITUTION EXPERIENCE WITH APRV
    Kommareddy-Sloane, Siri
    Madsen, Erik
    CRITICAL CARE MEDICINE, 2023, 51 (01) : 288 - 288
  • [10] Treatment of giant neurofibromas in extremities and trunk wall of neurofibromatosis type 1 patients: a Chinese 12-year single-institution experience
    Gao, Qianqian
    Yang, Zhe
    Ma, Ning
    Chen, Sen
    Li, Yangqun
    ANZ JOURNAL OF SURGERY, 2024, 94 (09) : 1524 - 1530